EP0865440B1
(de)
*
|
1995-12-08 |
2002-04-03 |
Janssen Pharmaceutica N.V. |
(imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
|
ES2182327T3
(es)
*
|
1997-06-02 |
2003-03-01 |
Janssen Pharmaceutica Nv |
Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos.
|
US20030114503A1
(en)
*
|
1997-06-16 |
2003-06-19 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
|
US6420555B1
(en)
*
|
1998-06-16 |
2002-07-16 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Imidazolyl derivatives
|
CA2335435A1
(en)
*
|
1998-06-16 |
1999-12-23 |
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R |
Imidazolyl derivatives
|
ID27199A
(id)
*
|
1998-07-06 |
2001-03-08 |
Janssen Pharmaceutica Nv |
Penghambat transferase protein farnesil untuk pengobatan artropatis
|
EE04582B1
(et)
|
1998-07-06 |
2006-02-15 |
Janssen Pharmaceutica N.V. |
Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis
|
FR2780892B1
(fr)
*
|
1998-07-08 |
2001-08-17 |
Sod Conseils Rech Applic |
Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
|
NZ509372A
(en)
|
1998-08-27 |
2003-08-29 |
Pfizer Prod Inc |
Substituted quinolin-2-one derivatives, pharmaceuticals thereof and their use for treating abnormal cell growth (e.g. cancer)
|
BR9913315A
(pt)
|
1998-08-27 |
2001-05-22 |
Pfizer Prod Inc |
Derivados de quinolin-2-ona úteis como agentes anticâncer
|
AU2478500A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6284755B1
(en)
|
1998-12-08 |
2001-09-04 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
UA71592C2
(uk)
*
|
1998-12-23 |
2004-12-15 |
Янссен Фармацевтика Н.В. |
Похідні 1,2-анельованого хіноліну, спосіб їх одержання (варіанти), фармацевтична композиція, що їх містить, проміжна сполука та спосіб її одержання
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
TR200201297T2
(tr)
|
1999-02-11 |
2002-06-21 |
Pfizer Products Inc. |
Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
|
US6143766A
(en)
*
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
EP1420015A1
(de)
*
|
1999-06-11 |
2004-05-19 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Imidazol-Derivate
|
FR2796943A1
(fr)
*
|
1999-07-30 |
2001-02-02 |
Aventis Pharma Sa |
Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
|
DK1233787T3
(da)
*
|
1999-11-09 |
2005-08-15 |
Sod Conseils Rech Applic |
Produkt, der inhiberer signaltransduktion fra heterotrimere G-proteiner, kombineret med et andet cancerbekæmpende middel til terapeutisk anvendelse i cancerbehandlingen
|
ES2212971T3
(es)
*
|
1999-11-30 |
2004-08-16 |
Pfizer Products Inc. |
Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
|
HN2000000266A
(es)
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
JP5491681B2
(ja)
*
|
2000-02-04 |
2014-05-14 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
|
US6838467B2
(en)
|
2000-02-24 |
2005-01-04 |
Janssen Pharmaceutica N. V. |
Dosing regimen
|
CA2397446A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica Inc. |
Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
|
WO2001064199A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with taxane compounds
|
AU2001252147A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations
|
CA2397349A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Ivan David Horak |
Farnesyl protein transferase inhibitor combinations with an her2 antibody
|
EP1261356A2
(de)
*
|
2000-02-29 |
2002-12-04 |
Janssen Pharmaceutica N.V. |
Kombination von farnesyl proteintransferase inhibitoren mit einer platin-koordinationsverbindung
|
WO2001064198A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
|
US20030186925A1
(en)
*
|
2000-02-29 |
2003-10-02 |
Palmer Peter Albert |
Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
|
JP2003525234A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
|
JP2003525255A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
|
AU2001244167A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
CA2397475A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with vinca alkaloids
|
US6844357B2
(en)
*
|
2000-05-01 |
2005-01-18 |
Pfizer Inc. |
Substituted quinolin-2-one derivatives useful as antiproliferative agents
|
JO2361B1
(en)
*
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
EP1322636A1
(de)
|
2000-09-25 |
2003-07-02 |
Janssen Pharmaceutica N.V. |
6-(substituierte phenyl)methyl)chinolin- und chinazolinderivate und deren verwendung als farneyl transferase inhibitoren
|
ES2261476T3
(es)
|
2000-09-25 |
2006-11-16 |
Janssen Pharmaceutica N.V. |
Derivados de quinolina y quinazolina que inhiben la farnesil-tranferasa como inhibidores de farnesil-tranferasa.
|
JP4974439B2
(ja)
*
|
2000-09-25 |
2012-07-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリノン誘導体
|
AU2002220559A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
|
EP1339709B1
(de)
*
|
2000-11-21 |
2009-06-24 |
Janssen Pharmaceutica N.V. |
Farnesyltransferase hemmende benzoheterocyclische derivate
|
ATE323490T1
(de)
*
|
2000-11-28 |
2006-05-15 |
Janssen Pharmaceutica Nv |
Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
|
WO2002050058A1
(en)
|
2000-12-19 |
2002-06-27 |
Pfizer Products Inc. |
Crystal forms of 6-[(4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl] -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production
|
JP4351444B2
(ja)
*
|
2000-12-27 |
2009-10-28 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する4−ヘテロシクリル−キノリンおよびキナゾリン誘導体
|
ATE319704T1
(de)
*
|
2000-12-27 |
2006-03-15 |
Janssen Pharmaceutica Nv |
Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
|
AU2002236813A1
(en)
*
|
2001-01-22 |
2002-07-30 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
ES2318000T3
(es)
*
|
2001-02-15 |
2009-05-01 |
Janssen Pharmaceutica Nv |
Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
|
CA2438421C
(en)
*
|
2001-03-12 |
2010-05-18 |
Janssen Pharmaceutica N.V. |
Process for the preparation of imidazole compounds
|
US20020151563A1
(en)
*
|
2001-03-29 |
2002-10-17 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
|
US6706699B2
(en)
|
2001-06-21 |
2004-03-16 |
Ariad Pharmaceuticals, Inc. |
Quinolines and uses thereof
|
US6713462B2
(en)
|
2001-06-21 |
2004-03-30 |
Ariad Pharmaceuticals, Inc. |
Quinolinones and uses thereof
|
US6740757B2
(en)
|
2001-08-29 |
2004-05-25 |
Pfizer Inc |
Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
|
US20030134846A1
(en)
*
|
2001-10-09 |
2003-07-17 |
Schering Corporation |
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
|
EP1458720B1
(de)
|
2001-12-19 |
2009-03-18 |
Janssen Pharmaceutica N.V. |
Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
|
DE60314381T2
(de)
*
|
2002-03-22 |
2008-02-21 |
Janssen Pharmaceutica N.V. |
Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
|
EP1497295B1
(de)
|
2002-04-15 |
2006-08-16 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US20030125268A1
(en)
*
|
2002-08-28 |
2003-07-03 |
Rybak Mary Ellen Margaret |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
JP4596916B2
(ja)
*
|
2002-09-05 |
2010-12-15 |
メディミューン,エルエルシー |
Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
CA2521826C
(en)
|
2003-04-11 |
2013-08-06 |
Jennifer L. Reed |
Recombinant il-9 antibodies and uses thereof
|
US20050003422A1
(en)
|
2003-07-01 |
2005-01-06 |
Mitch Reponi |
Methods for assessing and treating cancer
|
NZ544697A
(en)
*
|
2003-07-22 |
2009-03-31 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as inhibitors of c-fms kinase
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
AU2004286198C1
(en)
|
2003-08-18 |
2011-02-24 |
Medimmune, Llc |
Humanization of antibodies
|
EP1667973B1
(de)
*
|
2003-09-23 |
2013-12-04 |
Merck Sharp & Dohme Corp. |
Chinolin-kaliumkanalinhibitoren
|
WO2005089504A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
EP1744751A4
(de)
*
|
2004-03-18 |
2010-03-10 |
Brigham & Womens Hospital |
Verfahren zur behandlung von synucleinopathien
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
US20050288298A1
(en)
*
|
2004-03-18 |
2005-12-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
ES2308500T3
(es)
*
|
2004-05-03 |
2008-12-01 |
Janssen Pharmaceutica Nv |
Adicion diastereoselectiva de n-metilimidazol en sulfiniminas.
|
DE602005021878D1
(de)
|
2004-05-03 |
2010-07-29 |
Janssen Pharmaceutica Nv |
Diastereoselektives syntheseverfahren mit 6-brom-4-(3-chlorphenyl)-2-methoxychinolin
|
ES2308486T3
(es)
|
2004-05-03 |
2008-12-01 |
Janssen Pharmaceutica Nv |
Proceso de sintesis diastereoselectiva para la preparacion de compuestos de imidazol.
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
ES2403060T3
(es)
|
2004-11-05 |
2013-05-13 |
Janssen Pharmaceutica Nv |
Uso terapéutico de inhibidores de la farnesiltransferasa y métodos de control de la eficacia de los mismos.
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
EP1869192B1
(de)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Rahmenmischung von antikörpern
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
US20070004660A1
(en)
*
|
2005-06-10 |
2007-01-04 |
Baumann Christian A |
Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
|
US20060281788A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US20060281769A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
|
US20060281755A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
US20070093449A1
(en)
*
|
2005-10-14 |
2007-04-26 |
De Porre Peter M R |
Novel IV formulation of tipifarnib
|
JP2009521470A
(ja)
|
2005-12-23 |
2009-06-04 |
リンク メディシン コーポレイション |
シヌクレイン障害の治療
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
AR059898A1
(es)
|
2006-03-15 |
2008-05-07 |
Janssen Pharmaceutica Nv |
Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
WO2007124316A1
(en)
*
|
2006-04-20 |
2007-11-01 |
Janssen Pharmaceutica N.V. |
Heterocyclic compounds as inhibitors of c-fms kinase
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
JP5331681B2
(ja)
*
|
2006-04-20 |
2013-10-30 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
c−fmsキナーゼの阻害剤
|
PT2292663E
(pt)
|
2006-08-28 |
2013-11-04 |
Kyowa Hakko Kirin Co Ltd |
Anticorpos monoclonais humanos antagonistas específicos de light humano
|
US8173629B2
(en)
|
2006-09-22 |
2012-05-08 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
RS58936B1
(sr)
|
2007-01-10 |
2019-08-30 |
Msd Italia Srl |
Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
|
CA2679659C
(en)
|
2007-03-01 |
2016-01-19 |
Novartis Ag |
Pim kinase inhibitors and methods of their use
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
JO2959B1
(en)
|
2007-05-14 |
2016-03-15 |
جانسين فارماسوتيكا ان. في |
Mono-hydrochloric salts for histone dacetylase inhibitor
|
EP2152700B1
(de)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r-hemmer, zusammensetzungen und anwendungsverfahren
|
EP2160386B1
(de)
*
|
2007-05-23 |
2012-07-11 |
Allergan, Inc. |
Therapeutische ((phenyl)imidazolyl)methylchinolinylverbindungen
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
BRPI0816767B8
(pt)
|
2007-09-14 |
2021-05-25 |
Addex Pharmaceuticals Sa |
composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
|
US8252937B2
(en)
|
2007-09-14 |
2012-08-28 |
Janssen Pharmaceuticals, Inc. |
1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
ES2533874T3
(es)
|
2007-10-31 |
2015-04-15 |
Medimmune, Llc |
Armazón proteico
|
JP2011517313A
(ja)
|
2007-12-11 |
2011-06-02 |
ビアメト ファーマシューティカルズ,インク. |
金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
|
US8940771B2
(en)
|
2007-12-20 |
2015-01-27 |
Novartis Ag |
Organic compounds
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
ES2439291T3
(es)
|
2008-09-02 |
2014-01-22 |
Janssen Pharmaceuticals, Inc. |
Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
|
MX2011005096A
(es)
*
|
2008-11-13 |
2011-11-18 |
Link Medicine Corp |
Derivados de azaquinolinona y usos de los mismos.
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
BRPI0921113A2
(pt)
*
|
2008-11-13 |
2016-02-16 |
Link Medicine Corp |
tratamento de proteinopatias usando um inibidor de farnesil transferase.
|
WO2010060589A1
(en)
|
2008-11-28 |
2010-06-03 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
NZ596053A
(en)
|
2009-05-12 |
2013-05-31 |
Janssen Pharmaceuticals Inc |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
CN102439008B
(zh)
|
2009-05-12 |
2015-04-29 |
杨森制药有限公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
|
CN102480966B
(zh)
|
2009-06-12 |
2015-09-16 |
达娜-法勃肿瘤研究所公司 |
融合的杂环化合物及其用途
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
CN104945382B
(zh)
|
2009-10-14 |
2020-02-07 |
默沙东公司 |
提高p53活性的取代的哌啶和其用途
|
EP2519517B1
(de)
|
2009-12-29 |
2015-03-25 |
Dana-Farber Cancer Institute, Inc. |
Typ-ii-raf-kinase-hemmer
|
KR20130006664A
(ko)
|
2010-03-16 |
2013-01-17 |
다나-파버 캔서 인스티튜트 인크. |
인다졸 화합물 및 그의 용도
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CA3186328A1
(en)
|
2010-07-28 |
2012-02-02 |
Janssen Pharmaceutica Nv |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
US9029341B2
(en)
|
2010-08-17 |
2015-05-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
ES2536433T3
(es)
|
2010-11-08 |
2015-05-25 |
Janssen Pharmaceuticals, Inc. |
Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
|
US8993591B2
(en)
|
2010-11-08 |
2015-03-31 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
|
US9271967B2
(en)
|
2010-11-08 |
2016-03-01 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP3763740A1
(de)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und verwendungen davon
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
EP2770987B1
(de)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Neue verbindungen als erk-hemmer
|
PT2771342T
(pt)
|
2011-10-28 |
2016-08-17 |
Novartis Ag |
Derivados de purina e o seu uso no tratamento de doença
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
EP3453762B1
(de)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
MX360892B
(es)
|
2012-05-16 |
2018-11-20 |
Novartis Ag |
Régimen de dosificación para un inhibidor de cinasa pi-3.
|
EP4063391A1
(de)
|
2012-07-25 |
2022-09-28 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und verwendungen davon
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2882757B1
(de)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Verfahren zur herstellung heterocyclischer esterderivate
|
MX2015004041A
(es)
|
2012-09-28 |
2015-07-06 |
Merck Sharp & Dohme |
Compuestos novedosos que son inhibidores de erk.
|
JP2015533832A
(ja)
|
2012-10-09 |
2015-11-26 |
アイジェニカ バイオセラピューティクス インコーポレイテッド |
抗C16orf54抗体およびその使用方法
|
JP6250686B2
(ja)
|
2012-10-16 |
2017-12-20 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Rorγtのヘテロアリール結合させたキノリニルモジュレータ
|
AR093017A1
(es)
|
2012-10-16 |
2015-05-13 |
Janssen Pharmaceutica Nv |
MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO
|
JP6251277B2
(ja)
|
2012-10-16 |
2017-12-20 |
ヤンセン ファーマシューティカ エヌ.ベー. |
ROR−ガンマ−tのフェニル結合キノリニルモジュレーター
|
EP2909194A1
(de)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Hemmer der cyclinabhängigen kinase 7 (cdk7)
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
WO2014085216A1
(en)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
US10100123B2
(en)
|
2013-06-06 |
2018-10-16 |
Pierre Fabre Medicament |
Anti-C10orf54 antibodies and uses thereof
|
KR102362630B1
(ko)
|
2013-08-26 |
2022-02-15 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
시알릴-루이스 a에 대한 사람 항체 코드화 핵산
|
EP3041938A1
(de)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Kreisförmige polynukleotide
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
ES2770727T3
(es)
|
2013-10-15 |
2020-07-02 |
Janssen Pharmaceutica Nv |
Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
US9624225B2
(en)
|
2013-10-15 |
2017-04-18 |
Janssen Pharmaceutica Nv |
Quinolinyl modulators of RORγt
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
AU2014337122B2
(en)
|
2013-10-18 |
2019-01-03 |
Dana-Farber Cancer Institute, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
EP3057956B1
(de)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclische inhibitoren der cyclin-dependent-kinase 7 (cdk7)
|
MX2016007376A
(es)
|
2013-12-06 |
2017-05-11 |
Novartis Ag |
Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
|
DK3096790T3
(da)
|
2014-01-21 |
2019-10-07 |
Janssen Pharmaceutica Nv |
Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
|
DK3431106T3
(da)
|
2014-01-21 |
2021-03-15 |
Janssen Pharmaceutica Nv |
Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US10076512B2
(en)
|
2014-05-01 |
2018-09-18 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
US11311519B2
(en)
|
2014-05-01 |
2022-04-26 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
KR102614642B1
(ko)
|
2014-06-04 |
2023-12-19 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
강글리오사이드 gd2에 대한 사람 단클론 항체
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
DK3229838T3
(da)
|
2014-12-11 |
2020-10-19 |
Pf Medicament |
Anti-C10orf54-antistoffer og anvendelser deraf
|
CA2972239A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
HRP20230046T1
(hr)
|
2015-03-03 |
2023-03-03 |
Kymab Limited |
Protutijela, upotreba i postupci
|
JP6861166B2
(ja)
|
2015-03-27 |
2021-04-21 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
ES2844848T3
(es)
|
2015-04-21 |
2021-07-22 |
Eiger Biopharmaceuticals Inc |
Composiciones farmacéuticas que comprenden Lonafarnib y Ritonavir
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
HRP20211976T1
(hr)
|
2015-08-17 |
2022-03-18 |
Kura Oncology, Inc. |
Postupci liječenja bolesnika od raka inhibitorima farnezil transferaze
|
WO2017034877A1
(en)
*
|
2015-08-27 |
2017-03-02 |
Janssen Pharmaceutica Nv |
Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists
|
WO2017044858A2
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
KR20180073674A
(ko)
|
2015-11-02 |
2018-07-02 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
|
WO2017096017A1
(en)
|
2015-12-02 |
2017-06-08 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
EP3534885B1
(de)
|
2016-11-03 |
2021-01-20 |
Kura Oncology, Inc. |
Farnesyltransferase-inhibitoren zur verwendung bei der behandlung von krebs
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
US10954210B2
(en)
|
2016-12-08 |
2021-03-23 |
Hangzhou Solipharma Co., Ltd. |
Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof
|
US10851164B2
(en)
|
2017-04-13 |
2020-12-01 |
Aduro Biotech Holdings, Europe B.V. |
Anti-SIRPα antibodies
|
US20200131266A1
(en)
|
2017-05-31 |
2020-04-30 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
CA3065301A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
JP7256796B2
(ja)
|
2017-10-13 |
2023-04-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Thomsen-nouvelle(tn)抗原に対するヒト抗体
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
BR112020023559A2
(pt)
|
2018-05-18 |
2021-02-09 |
Kura Oncology, Inc. |
método para preparar um enantiômero de tipifarnib desejado e método para transformar uma amina enantiomericamente enriquecida
|
WO2020016459A1
(en)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Receptor for vista
|
EP3833668A4
(de)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
Prmt5-inhibitoren
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
AU2022399572A1
(en)
*
|
2021-11-30 |
2024-05-02 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
WO2023141082A1
(en)
*
|
2022-01-20 |
2023-07-27 |
Teva Czech Industries S.R.O. |
Solid state forms of tipifarnib and process for preparation thereof
|